Prostate Cancer Is Rising in Filipino Men. It Is Almost Always Found Too Late.

What the Latest Data Shows About the Philippine Prostate Cancer Burden

The GLOBOCAN 2024 estimates, the most recent global cancer data published by the IARC in July 2026, place prostate cancer as the second most common cancer among Filipino men with 9,195 new cases in 2024, behind only lung cancer. This marks a shift from the 2020 data, when prostate cancer ranked third. The disease now accounts for 15 percent of all new male cancer cases in the country. Deaths reached 4,170 in 2024, with an age-standardized mortality rate of 14.2 per 100,000 men. Approximately 19,663 Filipino men are currently living with prostate cancer within five years of diagnosis. At the global level, prostate cancer ranked fourth overall across all cancers and all sexes in 2024, accounting for 7.5 percent of all new cancer cases worldwide.

What distinguishes the Philippine experience from that of higher-income countries is the mortality trajectory. A 2024 analysis published in European Urology examining global prostate cancer incidence and mortality trends found that while most countries in Europe, North America, Oceania, and Latin America have seen declining mortality rates, largely attributable to PSA-based screening and improved treatments, the Philippines is among only nine countries where prostate cancer mortality rates are still increasing. Despite being more prevalent in developed countries, age-standardized prostate cancer mortality rates are disproportionately higher in developing countries like the Philippines. The gap between incidence and survivorship reflects a fundamental difference in stage at diagnosis: when cancer is found early and confined to the prostate, outcomes are excellent. When it is found after it has spread to lymph nodes or bones, treatment becomes palliative rather than curative.

Why Prostate Cancer Is So Dangerous When Found Late and So Treatable When Found Early

The prostate is a walnut-sized gland located below the bladder in men, responsible for producing fluid that forms part of semen. Prostate cancer develops when cells in the gland begin to grow uncontrollably. In its earliest stages, prostate cancer is entirely confined within the gland, produces no symptoms, and is highly curable with surgery, radiation, or in selected cases active surveillance. The five-year survival rate for localized prostate cancer approaches 100 percent in settings with adequate early detection and treatment. Once the cancer spreads beyond the prostate capsule to regional lymph nodes, the five-year survival rate drops to approximately 72 percent. Once it metastasizes to distant organs, particularly the bones where prostate cancer most commonly spreads, the five-year survival rate falls to around 28 percent. The trajectory from curable to life-limiting depends almost entirely on when the cancer is detected relative to its stage of spread.

The complication is that early prostate cancer produces no symptoms whatsoever. Urinary symptoms such as difficulty urinating, weak urine stream, frequent nighttime urination, and blood in urine or semen can occur with prostate cancer, but they are more commonly caused by benign prostatic hyperplasia, an entirely non-cancerous enlargement of the prostate that affects most men over 50. Many Filipino men who present with these symptoms receive treatment for BPH and are never evaluated for cancer. Without proactive screening through a PSA blood test or digital rectal examination, prostate cancer grows silently until it is advanced enough to cause symptoms from spread, at which point curative treatment is no longer possible.

The Specific Barriers Filipino Men Face

A peer-reviewed analysis of barriers to prostate cancer care in the Philippines, published in Frontiers in Urology in 2023 and updated in 2026, identified a layered set of obstacles that operate at the individual, health system, and policy level simultaneously. At the individual level, awareness of prostate cancer among Filipino men is low, and cultural norms that discourage men from proactively seeking health care, particularly for conditions involving the genital and urinary system, significantly delay consultation. The DRE, or digital rectal examination, which involves physical examination of the prostate through the rectum, is a source of significant reluctance and avoidance among Filipino men, contributing to low uptake of prostate cancer screening even in settings where it is available.

At the health system level, access to diagnostic technology remains limited relative to neighboring countries. A baseline assessment from 2013 found only 1.09 CT machines and 0.3 MRI units per one million Filipinos, and while infrastructure has expanded since then, rural and provincial access to imaging needed for prostate cancer staging remains uneven. Genetic testing and molecular biomarker analysis relevant to prostate cancer treatment planning are not readily available domestically and frequently require sending samples abroad. At the policy level, PhilHealth's Z Benefit Package for prostate cancer covers only low to intermediate-risk disease. The most recently available data, from 2023, found only seven hospitals across three administrative regions contracted to offer it, a figure that reflects how geographically concentrated access to this benefit remains. Research from the ACTION Study, which examined financial catastrophe associated with cancer treatment among Filipino patients, found that having insurance coverage lowered odds of treatment discontinuation but did not prevent financial catastrophe, reflecting the inadequacy of benefit values relative to actual treatment costs for advanced disease.

The cost of PSA testing itself, while not prohibitive for higher-income patients at a few hundred to a few thousand pesos at private laboratories, remains a barrier in lower-income communities where the test is not routinely included in public health facility offerings. Local government units occasionally hold free DRE screening drives during men's health month, but these reach a small fraction of the at-risk population. Malasakit Centers in public hospitals can consolidate financial assistance for cancer patients, but this requires a diagnosis to have already been made.

Who Should Be Screened and What Screening Involves

The Philippine Urological Association recommends that men discuss prostate cancer screening with their physician beginning at age 50 for average-risk individuals, and at age 40 to 45 for men with a first-degree relative who had prostate cancer or for Filipino men of African ancestry, both of whom face higher baseline risk. Filipino men, both those living in the Philippines and those in diaspora populations, have been documented as having among the highest prostate cancer incidence and mortality rates of any Asian ethnic group, including in studies conducted in countries where PSA screening is widely practiced. This suggests a real biological risk elevation that is not fully explained by screening differences alone.

The PSA test is a blood test measuring prostate-specific antigen, a protein produced by both normal and cancerous prostate cells. An elevated PSA does not diagnose cancer: it indicates that further evaluation is warranted, typically through imaging and prostate biopsy. PSA screening is a probabilistic tool that detects cancers at earlier stages than symptom-driven diagnosis, which is precisely why it has been associated with mortality declines in countries where it is widely used. The conversation about whether and when to screen, which involves individual preferences about the trade-offs between early detection and the possibility of diagnosing slow-growing cancers that might never cause harm, is one every Filipino man over 45 should be having with a physician.

• Men aged 50 and above with no family history of prostate cancer should discuss PSA screening with their doctor; men with a father or brother who had prostate cancer should start this conversation at age 40 to 45
• Symptoms including difficulty urinating, weak or interrupted urine flow, blood in urine or semen, bone pain in the lower back or hips, and unexplained weight loss should prompt immediate consultation regardless of age
• PhilHealth's Z Benefit Package covers low to intermediate-risk prostate cancer treatment worth 100,000 pesos for eligible male members aged 70 and below at contracted facilities
• The Cancer Assistance Fund and Malasakit Centers at public hospitals can provide additional financial support for prostate cancer patients who need assistance beyond PhilHealth coverage